Urinary albumin excretion is a powerful predictor of progressive cardiovascular and renal disease. In rats and humans, administration of a synthetic vasopressin analogue, 1-desamino-8-D-arginine-vasopressin, increases urinary albumin excretion; however, it is unknown if endogenous vasopressin levels influence albumin excretion. To determine this we measured copeptin, a marker of endogenous vasopressin levels, and its association with urinary albumin excretion in 7593 patients in the PREVEND study, a prospective population based, observational cohort. Urinary albumin excretion was measured in two consecutive 24-h urine samples by nephelometry while copeptin was measured by an immunoassay. Median copeptin concentrations were significantly higher in males than females and high levels were associated with significantly lower 24-h urine volumes of high osmolarity. With increasing quintiles of copeptin levels, the percentage of microalbuminuric subjects increased from 13 to 25 for males and from 8 to15 for females. This association was independent of age and other potential confounders; however, we found an interaction between age and copeptin in their association with urinary albumin excretion. Our study shows that plasma copeptin levels are associated with microalbuminuria, consistent with the hypothesis that vasopressin is involved in urinary albumin excretion. If future studies show that this association is causal, then drinking more water or pharmacological intervention to decrease plasma vasopressin may have beneficial effects on the kidney, especially in the elderly.
Urinary albumin excretion (UAE) is a powerful predictor of cardiovascular mortality and progressive renal function deterioration, not only in diabetics, but also in the general population. 1, 2 It is assumed that UAE not only reflects glomerular damage, but is also related to systemic endothelial dysfunction. Lowering albuminuria is associated with better renal 3 and cardiovascular 4 outcome. Identifying modifiable factors that cause increase in UAE is, therefore, important, since intervention directed to these factors might be expected to result in better renal and cardiovascular prognosis.
Vasopressin has been hypothesized as one of these modifiable factors. Vasopressin is also known as antidiuretic hormone since it binds to the V2 receptors in the collecting ducts, inducing the insertion of the molecular water channel aquaporin-2 in the luminal membrane of principal cells. This mediates water reabsorption, thereby reducing water excretion. 5 Despite its importance for normal water regulation in the body, vasopressin also has been reported to exert deleterious effects on the kidney. Administration of 1-desamino-8-D-arginine vasopressin (a vasopressin-receptor agonist) to rats and humans induces albuminuria 6, 7 and inhibition of vasopressin by drinking water or V2 antagonism reduces proteinuria in rats with renal failure 8, 9 and diabetes. 10 Interest in pleiotropic effects of vasopressin has risen because vasopressin antagonists are expected to become available for clinical use within the next years. Human studies investigating the influences of endogenous vasopressin on albuminuria are, however, lacking. Presumably this is due to the fact that direct measurement of vasopressin in humans is problematic. More than 90% of vasopressin in the circulation is bound to platelets; 11 vasopressin is unstable in isolated plasma 11 and most vasopressin assays have relatively limited sensitivity. Recently, an assay has been developed to measure copeptin, the C-terminal portion of the precursor of vasopressin. Copeptin has been proven to be a reliable marker of vasopressin secretion and a useful substitute for circulating vasopressin concentration in clinical routine. 12, 13 These characteristics make copeptin a promising marker, which allows for the first time (indirect) measurement of vasopressin in epidemiological studies.
Given the aforementioned, we hypothesized that in the general population copeptin (a surrogate marker of vasopressin) is associated with albuminuria, and investigated this in an observational, cross-sectional study.
RESULTS
Characteristics of participating subjects are presented for quintiles of copeptin in Table 1 separately for gender. A total of 7,593 subjects (47.2% male, aged 49±13 years) were analyzed. Median copeptin concentration in these subjects was 4.7 pmol/l (2.9-7.5), with significantly higher concentration in males (6.2 pmol/l(4.1-9.5)) than in females (3.6 pmol/l (2.4-5.5), Po0.001). Table 2 depicts the associations between copeptin and these variables for males and females. As copeptin concentration is significantly associated with age, an additional column is included to represent the association adjusted for age. When adjusted for age, copeptin concentration was positively associated with serum creatinine, blood pressure, body mass index (BMI), and sodium intake levels in males and females, whereas the association with estimated glomerular filtration rate (eGFR) was negative. Associations between copeptin and smoking and use of angiotensinconverting enzyme inhibitors/angiotensin-II-receptor blockers (ACEi/ARBs) are significant in females and not in males, while plasma glucose and plasma cholesterol levels are significant in males but not in females. The association between copeptin level and blood pressure is presented in the table for the whole group. For subjects on antihypertensive medication (males n ¼ 494, females n ¼ 510) this association is not significant. For those who do not receive antihypertensive treatment, the associations between copeptin and blood pressure are approximately similar to that of the whole group (depicted in Table 2 ).
To investigate whether vasopressin concentration is consistent with normal physiology, we tested the associations between copeptin and 24-h urinary volume and 24-h urinary osmolarity. A high concentration of copeptin was associated with low 24-h urinary volume (in males R ¼ À0.27 and in females R ¼ À0.23, both Po0.001) and high urinary osmolarity (in males R ¼ 0.27 and in females R ¼ 0.23, both Po0.001). The correlation of copeptin with overall calculated urinary osmolarity was stronger than that with the single determinants of the calculated osmolarity (for copeptin and urinary sodium concentration R-value was 0.25 for males and 0.22 in females; for urinary potassium concentration this was 0.16 for males and 0.15 for females; and for urinary urea concentration, R-value was 0.25 and 0.21, respectively). The associations of copeptin with 24-h urinary volume and 24-h urinary osmolarity are presented in Figure 1 . Twenty-four-hour urinary volume is highest in quintile-1 and lowest in quintile-5 (1.74 ± 0.51 versus 1.36 ± 0.44 l for males and 1.82 ± 0.60 versus 1.43 ± 0.52 l for females), whereas urinary osmolarity varies an opposite manner (533±155 versus 667±183 mOsm/l for males and 418±133 versus 530±170 mOsm/l for females). The osmolar load is not different between quintile-1 and quintile-5 for each gender (for males 876 mOsm in quintile 1 versus 841 Osm in quintle-5, P ¼ 0.06; and for females 707 versus 698 mOsm, P ¼ 0.3). Median UAE for the whole group was 9.3 mg/24 h (6.4-16.8) and 986 (13%) of the subjects had microalbuminuria (microalbuminuria is defined as UAE X30 mg/ 24 h). Copeptin level was significantly associated with UAE (R ¼ 0.20, Po0.001). This association is depicted in Figure 2 . UAE is higher in the quintile with higher copeptin values: quintile-1: 9.4 mg/24 h (6.5-17.2) for males and 7.3 mg/24 h (5.5-11.7) for females, and quintile-5: 13.4 mg/24 h (8.1-29.8) for males and 10.0 mg/24 h (6.6-18.3) for females. Also depicted in Figure 2 is the percentage of microalbuminuric subjects per quintile of copeptin. The percentage of microalbuminuric subjects is highest in the highest quintile of copeptin.
In Figure 3 the association between copeptin and UAE is shown in addition to that of modifiable factors that are known to influence UAE (mean arterial pressure (MAP), BMI, fasting plasma glucose, and cholesterol). For this purpose gender-stratified quintiles were made for every factor specifically. This figure shows that the association between MAP and UAE is the strongest and that the association between copeptin and UAE is comparable to that between glucose, BMI or cholesterol, and UAE. R-values for the association between MAP, glucose, BMI, and cholesterol versus UAE are respectively 0.36, 0.25, 0.21 and 0.12.
The association between copeptin and UAE was also investigated using copeptin as a continuous variable in multivariate regression analyses. We adjusted this association in a multivariate model for several potential confounders. Despite the fact that our regression model did not show indications for an interaction with gender and that the regression coefficients for males and females were not different (P ¼ 0.11 for the crude model and 0.37 for the fully adjusted model), results are depicted for males and females separately in Table 3 . The association was significant with a b-value of 0.25 for males and 0.19 for females, both Po 0.001 (Table 3 , model 1). Adjusted for gender, the association remained significant. Further adjustment for potential cardiovascular confounders (model 3) and medication that could potentially influence both vasopressin (and thus copeptin concentration) and UAE (model 4), did not materially influence the association between copeptin and UAE.
Urinary osmolarity was also associated with UAE with a standardized b-value of À0.05 for males and 0.07 for females, both Po0.001. This association was independent of age, gender, potential cardiovascular confounders, and use of diuretics and/or ACEi/ARBs.
In the crude and the full corrected model, an interaction was found between age and log copeptin concentration on UAE (Po0.001). In Figure 4 , the association between copeptin and UAE is depicted stratified for quintiles of age. Copeptin was associated with UAE in all age groups, but this association is the strongest when subjects are older. In the youngest age quintile (age 28-36 years), copeptin concentration rose from 1.9 pmol/l (1.6-2.7) to 11.2 pmol/l (8.3-14.4) from the first to the fifth quintile of copeptin, with median UAE rising from 7.5 mg/24 h (5.8-10.4) to 8.5 mg/24 h (6.2-13.6). In the oldest age quintile of our study (age 62-75 years), copeptin concentration rose from 2.0 mg/24 h (1.5-2.8) to 11.9 mg/24 h (9.3-15.8) while median UAE rose from 11.1 mg/24 h (7.0-23.5) to 18.2 mg/24 h (9.4-40.8). Twenty-four-hour urinary volume and 24-h urinary osmolarity were significantly different, with 24-h urinary volume being higher and 24-h urinary osmolarity being lower in the oldest age group when compared with the youngest age group (in the highest quintile of copeptin, 1,434±465 ml and 543±163 mOsm/l for the oldest quintile versus 1259±485 ml and 673±202 mOsm/l in the youngest quintile).
Of note, apart from the interaction of age and log copeptin concentration on UAE, we did not find any other interactions between baseline characteristics and log copeptin concentration on UAE. The results we obtained in the various sensitivity analyses (stratified for ACEi/ARB and diuretics use (yes/no), with or without outliers of copeptin, with or without diabetic subjects, and without subjects with nonfasting blood sample and without subjects with 420% difference in creatinine excretion in two consecutive 24-h urine collections and repeated with IDMS-traceable creatinine levels), were essentially similar to those from our primary analyses. 
DISCUSSION
In this study, we found copeptin levels to be higher in males than females, corresponding with lower urine volumes and higher urinary osmolarity in males versus females. In both males and females, high copeptin concentration (a surrogate for vasopressin) is associated with low 24-h urinary volume and high 24-h urinary osmolarity. Furthermore, our study shows that copeptin is associated with UAE: higher the copeptin level, higher the UAE and the more microalbuminuric the subjects, again, both in males and in females. This association remained significant after adjustment for age, potential cardiovascular confounders, and medication that could potentially influence both vasopressin (and thus copeptin) secretion and UAE. The association between copeptin and UAE was found to be most pronounced for older subjects. The observed association between vasopressin and UAE is consistent with our hypothesis that vasopressin induces albuminuria.
Animal studies showed that administration of 1-desamino-8-D-arginine-vasopressin (a V2-receptor agonist) induced an increase in urinary protein excretion and a more rapid decline of renal function. 14 Also in humans, short-term 1-desamino-8-D-arginine-vasopressin administration has been shown to result in an increase in UAE. 6 In contrast, vasopressin inhibition by drinking water 8 or by V2 antagonism 15 led to a decrease in proteinuria in rats with renal failure. In a rat model of diabetes mellitus, chronic treatment with a vasopressin V2 antagonist prevented the rise in albuminuria seen in untreated rats. 10 In these untreated rats with diabetes mellitus, albuminuria was significantly correlated with free-water reabsorption, suggesting an association between albuminuria and vasopressin.
The unfavorable renal effects of vasopressin have been argued to be partly due to an effect on blood pressure. Vasopressin may contribute to hypertension either through a direct effect on vascular smooth muscle through activation of the V1a receptor, 16 or by V2-receptor-dependent tubular effects. The latter includes enhancement of sodium reabsorption in the collecting duct 17 and increase in intrarenal urea recycling, which participates in the urine-concentrating mechanism. The latter may indirectly modify NaCl concentration at the macula densa, thereby influencing tubuloglomerular feedback, leading to renin release, hypertension, glomerular hyperfiltration, and proteinuria. 18, 6 In our study, however, the association between copeptin and UAE was independent of systemic blood pressure, indicating that other mechanisms of action may be important. Furthermore, urinary osmolarity was independently associated with UAE, but less strong than the association between copeptin and UAE, suggesting that besides the antidiuretic effect of vasopressin, other effects (e.g., pressor effects) may also be involved in the relationship of copeptin with UAE.
Induction of specific glomerular hyperfiltration or decreased tubular albumin reabsorption might be mechanisms underlying this relationship.
We also found copeptin to be associated with renal function. Subjects with higher levels of copeptin had lower renal function. Reasons for this phenomenon could be that copeptin causes renal function decline or that subjects with low renal function are less sensitive to the actions of copeptin/ vasopressin. The fact that copeptin is partly cleared by the kidney 19 is not a likely explanation, because negative feedback loops will downregulate copeptin/vasopressin secretion. We investigated potential interactions between log copeptin concentration on the one hand and gender, age, and baseline renal function on the other hand, because we wanted to investigate whether there are certain subgroups of subjects that are more susceptible to copeptin's influences. We found no interaction between copeptin and gender or renal function, suggesting that the association between log copeptin concentration and UAE is essentially similar in men and women, and independent of renal function. The interaction between age and copeptin was, however, significant, suggesting that the association between log copeptin concentration and UAE is most pronounced in older subjects (Figure 4 ). This could be explained because they might be more vulnerable to the influence of vasopressin or because they have been longer exposed to high vasopressin levels. Another explanation for this interaction could be that older subjects might have decreased tubular reabsorption. This could result in both increased UAE and decreased concentration capacity (24-h urinary volume is higher and 24-h urinary osmolarity is also lower in the oldest quintile), or become resistant to vasopressin with age.
The association between copeptin and UAE has an R-value of 0.20. This relatively low R-value indicates that other factors also contribute to UAE. Compared with well acknowledged modifiable risk factors for UAE, the association between copeptin and UAE is less strong than that between MAP and UAE, but of approximately similar strength as BMI, cholesterol, and glucose (indicated by Figure 3 and the R-values of these associations). It is furthermore important to note that the association between copeptin and UAE was independent of these potential confounders (Table 2) .
Copeptin levels are likely to fluctuate according to changes in volume or plasma osmolarity. This raises the question whether the observed association will be of relevance for renal function or albuminuria in the long run. There is, however, evidence that copeptin levels are not only dependent on volume status and plasma osmolarity, but also to a certain extent are genetically determined. Subjects who have higher thirst and vasopressin threshold as genetic trait, [20] [21] [22] could, therefore, be at greater renal risk. These subjects with higher vasopressin level as a genetic trait and/or elderly subjects are most likely to profit from intervention (as drinking water or administration of a vasopressin-receptor antagonist).
We acknowledge that this study has limitations. First, it is a cross-sectional epidemiological study. Therefore no certain causal relationship can be proven. A third factor could underlie both copeptin level and albuminuria. For instance, subjects with higher UAE have more risk factors and a greater extent of subclinical interstitial injury and subsequent reduction of urine-concentration capacity. The observation that the association remains significant in the multivariate regression analysis suggests that this association is independent of possible confounding factors. It is, however, possible that residual confounding remained even in multivariateanalysis, because it is hard to adjust completely for the duration or severity of each risk factor for the extent of tubulointerstitial injury and impairment of water-concentration capacity. Additional research is needed to point out a mechanism underlying the observed association. Furthermore, our study consisted of predominantly Caucasian people, making extrapolation of our results to other ethnicities difficult.
Strengths of our study, as far as we know, are that, this is the first study to investigate the association between endogenous vasopressin and UAE. It confirms the results obtained with 1-desamino-8-D-arginine-vasopressin administration in animals and humans. Furthermore, this study has been performed with a large number of subjects, with extensive information on a large number of covariates.
In conclusion, our study shows that copeptin (a reliable substitute for vasopressin) is associated with UAE and microalbuminuria, consistent with the hypothesis that vasopressin induces UAE. If it is true that vasopressin induces albuminuria, suppressing vasopressin by administration of a vasopressin-receptor antagonist or simply by drinking more water might be beneficial for the kidney, especially in the elderly.
MATERIALS AND METHODS Study design and population
This study is part of the Prevention of Renal and Vascular End Stage Disease (PREVEND) Study, a cohort study that investigates the predictive value of UAE for renal and cardiovascular disease progression. All inhabitants of the city of Groningen between the ages 28 and 75 years (85,421 subjects) were asked to provide a morning urine sample and to fill a short questionnaire on demographics and cardiovascular history. A total of 40,856 subjects (47.8%) responded. After exclusion of subjects with insulindependent diabetes mellitus and pregnant women, all others with urinary albumin concentration X10 mg/l, together with a randomly selected control group, were invited. Finally, 8592 subjects completed the total screening program, rendering the actual screening cohort. Details of this study have been published elsewhere. 23, 24 For this study, subjects with a missing copeptin value (n ¼ 888, missing samples), missing 24-h urine collections (n ¼ 8), or non-fasting blood sample (n ¼ 103) were excluded, leaving 7593 subjects for analysis. The PREVEND study was approved by the medical ethics committee of our institution and was conducted in accordance with the guidelines of the Declaration of Helsinki Principles. All participants gave written informed consent.
Measurements and definitions
Participants completed two visits at our outpatient unit. Height and weight were measured. Information on drug use was provided by data from community pharmacies. During the first and second visit, blood pressure was measured on the right arm, in supine position, every minute for 10 and 8 min, respectively, with an automatic device (Dinamap XL Model 9300; Johnson-Johnson Medical, Tampa, FL, USA). Two 24-h urine samples were collected after thorough oral and written instructions on how to perform urine collection, and fasting blood sample was drawn.
Urinary albumin concentration was determined by nephelometry (BNII; Dade Behring Diagnostics, Marburg, Germany). Concentrations of sodium and potassium were measured in urine, and cholesterol and glucose levels were measured in serum using standard methods. Creatinine concentration was measured using Kodak Ektachem dry chemistry (Eastman Kodak, Rochester, NY, USA). Copeptin level was measured by a new sandwich immunoassay (B.R.A.H.M.S. AG, Hennigsdorf/Berlin, Germany), which was based on the assay described previously. 12 The assay was modified as follows: the capture antibody was replaced by a murine monoclonal antibody directed to amino acids 137-144 of proAVP. This modification improved the sensitivity of the assay. The lower detection limit was 0.4 pmol/l and the functional assay sensitivity (20% inter-assay coefficient of variation) was less than 1 pmol. 25 BMI was calculated as weight in kilograms (kg) divided by height in square meters (measured to the nearest 0.5 kg and 0.5 cm, respectively). History of coronary heart disease was defined as selfreported myocardial infarctions, cardiac operations, percutaneous transluminal coronary angioplasty, or cerebrovascular accident. This definition of coronary heart disease would probably misclassify subjects with unrecognized or silent coronary heart disease. 26 Systolic and diastolic blood pressure were measured as mean of the last two measurements of the two visits. These blood pressure values were used to calculate mean arterial pressure using the standard formula 2/3 diastolic blood pressure þ 1/3 systolic blood pressure. UAE was calculated as the mean of the two 24-h urine excretions. Included in our definition of diuretic use are all agents mentioned under C03 of the Anatomical Therapeutic Chemical (ATC) classification system (low-ceiling diuretics, thiazides, lowceiling diuretics, excl thiazides, high-ceiling diuretics, potassiumsparing agents, diuretics, and potassium-sparing agents in combination and combinations including these agents). Diabetes was defined as use of oral antidiabetic medication, a fasting glucose 47.0 mmol/l or, in case only a non-fasting sample was available, a non-fasting plasma glucose 411.1 mmol/l). Sodium excretion was used as a surrogate for sodium intake. Creatinine values were used to calculate eGFR, using the modification of diet in renal disease formula. 27 In early PREVEND papers, creatinine has not been reported as IDMStraceable creatinine. To keep reports of creatinine in PREVEND papers consistent over time, creatinine is always provided as non-IDMStraceable values. We have, however, validated creatinine against IDMS and used this as an additional sensitivity analysis. Microalbuminuria was defined as an UAE 430 mg/24 h. Urinary osmolarity was calculated as 2 * (Urinary sodium concentration þ Urinary potassium concentration) þ Urinary urea concentration. This formula is not validated in our cohort, but extracted from the literature. 28, 29, 19 Statistical analyses Analyses were performed with SPSS version 16.0 (SPSS Inc., Chicago, IL, USA). Parametric variables are expressed as mean±s.d., whereas non-parametric variables are given as median (interquartile range). Skewed data, such as C-reactive protein (CRP), were normalized by logarithmic transformation in analyses. A two-sided Po0.05 was considered to indicate statistical significance.
To visualize associations with copeptin, the study population was subdivided into quintiles of copeptin concentration. Since males have a significantly higher copeptin concentration than females, 13 when not depicted specifically separately, these quintiles were stratified for gender. P-values for differences between these quintiles were obtained using analysis of variance or Kruskal-Wallis test.
Gender-stratified quintiles were also made for BMI, blood pressure, cholesterol, fasting glucose, and CRP (other modifiable factors that are known to be associated with increase in UAE in the non-diabetic population 30 ). This was done to compare the association between copeptin concentration and UAE with the association between these other modifiable factors and UAE.
To investigate whether copeptin concentration is associated with other variables, multiple regression analysis was performed. Logarithmic transformation of copeptin was applied to fulfill the requirement of equal distribution of the residuals. This was performed for the whole group and for males and females separately, both crude as well as adjusted for age.
To investigate the association between copeptin and UAE, logarithmic transformation of UAE was also applied and linear regression was performed. Stepwise, various models were built to adjust for possible confounding variables for males and females separately. First the association between log copeptin concentration and log UAE was investigated crude; second, it was adjusted for age and gender; third, adjusted for potential cardiovascular confounders (MAP, BMI, smoking, glucose, cholesterol, CRP, and eGFR); and, finally, adjusted for medication that could potentially influence both vasopressin secretion as well as UAE (diuretics and ACEi/ARB). The same models were used to investigate the association between urinary osmolarity and UAE in multiple regression analyses. Interactions between baseline characteristics and log copeptin concentration were tested in the multivariate model with UAE being the dependent variable.
Various sensitivity analyses were performed. To test whether use of diuretics would not only influence copeptin concentration, but also UAE, the analyses were also performed separately for subjects with and without diuretic use. Analyses were also performed stratified for medication influencing the renin-angiotensin system (ACEi and ARBs, yes/no) and for diabetic status (yes/no). All analyses were repeated, first, without outliers for copeptin (defined as a measurement, which falls more than 1.5 times the interquartile range above the third quartile or below the first quartile 31 ); second, we repeated the analyses with creatinine values that were IDMStraceable. Finally, all analyses were repeated excluding subjects with 420% difference in creatinine excretion in two consecutive 24-h urine collections as this may indicate incompleteness of urine collection.
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